Progress and Perspectives on HIV-1 microbicide development  by Alexandre, Kabamba B. et al.
Virology 497 (2016) 69–80Contents lists available at ScienceDirectVirologyhttp://d
0042-68
n Corr
E-mjournal homepage: www.elsevier.com/locate/yviroProgress and Perspectives on HIV-1 microbicide development
Kabamba B. Alexandre a,n, Hazel T. Mufhandu a, Grace M. London b, E. Chakauya a,
M. Khati a,c
a Council for Scientiﬁc and Industrial Research, Pioneering Health Sciences Laboratory, Biosciences Unit, Pretoria, Gauteng, South Africa
b Department of Health Free State District Health Services and Health Programs, South Africa
c University of Cape Town and Groote Schuur Hospital, Department of Medicine, Cape Town, South Africaa r t i c l e i n f o
Article history:
Received 12 June 2016
Returned to author for revisions
1 July 2016
Accepted 4 July 2016






22/& 2016 The Authors. Published by Elsevier
esponding author.
ail address: AAlexandre@csir.co.za (K.B. Alexana b s t r a c t
The majority of HIV-1 infections occur via sexual intercourse. Women are the most affected by the
epidemic, particularly in developing countries, due to their socio-economic dependence on men and the
fact that they are often victims of gender based sexual violence. Despite signiﬁcant efforts that resulted in
the reduction of infection rates in some countries, there is still need for effective prevention methods
against the virus. One of these methods for preventing sexual transmission in women is the use of
microbicides. In this review we provide a summary of the progress made toward the discovery of af-
fordable and effective HIV-1 microbicides and suggest future directions. We show that there is a wide
range of compounds that have been proposed as potential microbicides. Although most of them have so
far failed to show protection in humans, there are many promising ones currently in pre-clinical studies
and in clinical trials.
& 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
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developing world, Africa in particular, remains the epicentre of the
epidemic (http://www.who.int/gho/hiv/en/). In developing coun-
tries HIV-1 epidemic is characterized by a high proportion of in-
fected women compared to men. This can be explained by women
socio-economic dependence on men, domestic violence, high in-
cidence of rape, cultural norms and women inability to negotiate
safe sex practices, such as the use of condom, with their male
partners (Elias and Coggins, 1996). These factors are among the
driving forces behind the search for a female-controlled HIV-1
prevention method such as the use of microbicides, which are
cervico-vaginally applied products that can prevent male to female
transmission of the virus.
Many agents have been proposed as microbicide candidates to
prevent HIV-1 infection at the site of mucosal transmission (Le-
derman et al., 2006). Some of these agents are speciﬁc inhibitors of
HIV-1 infection while others are non-speciﬁc. The non-speciﬁc
inhibitors include compounds that modify the cervico-vaginal
environment (vaginal milieu protectors) such as buffering agents,
those that interact with the positively charged viral envelope
known as polyanionic polymers, and envelope inhibitors such as
lectins. The speciﬁc inhibitors include antibodies and reverse
transcriptase inhibitors such as tenofovir. Some HIV-1 microbicide
candidates have already been tested in clinical trials while most
are still in developmental stages. Here we review these com-
pounds together with their potential modes of delivery.Fig. 1. Different zones of the stratiﬁed epithelial cell lining. The ﬁve zones of the
epithelial cell lining found in the vaginal tract and ectocervix. Cells in the two
upper-most zones have a ﬂattened appearance. An intact epithelial cell lining does
not allow particles the size of an HIV-1 virus to pass through.2. Constitution of the female genital tract and male-to-female
transmission of HIV-1
The female genital tract comprises the vaginal tract and the
cervix; and the latter is divided into ectocervix and endocervix.
Both the vaginal tract and cervix are covered by a stratiﬁed
squamous epithelial cell lining starting in the vagina and ending at
the ectocervix (Coombs et al., 2003; Shattock and Moore, 2003).
This lining is made of ﬁve zones namely; the corniﬁed, the con-
densation, the clear, the parabasal and the basal zone (Fig. 1). In
contrast, the epithelial cell lining in the endocervical canal has
only one layer, a structure that makes it vulnerable to disruptions
such as those caused by sexual intercourse induced microtrauma
(Miller and Shattock, 2003; Norvell et al., 1984). This being said,
the epithelial cell lining in the vaginal tract and ectocervix is 15
times larger than that found in the endocervix, thus, offering a
larger surface area and more entry points for the virus (Hladik and
McElrath, 2008).
In the vagina and cervix many HIV-1 target cells are found in
and under the epithelial cell lining (Fig. 2A). These include Lan-
gerhans cells (LC), located within the lining and believed to play an
important role in mediating the virus crossing of the genital mu-
cosa (Shattock and Moore, 2003). Studies showed that after ex-
posure intraepithelial LCs can internalize HIV-1 in their cyto-
plasmic compartments and migrate out of the epithelium, through
the basal zone, to spread it to other sites (Ballweber et al., 2011;
Hladik et al., 2007). Virus internalization by these cells appears not
to be mediated by langerin as it is the case for epidermal LCs. The
bypassing of this receptor during HIV-1 endocytosis may promote
survival since langerin mediates the virus degradation in the Bir-
beck granules (de Witte et al., 2007; Savina et al., 2006). In addi-
tion to endocytosis LCs can be productively infected by the virus,
although, the extent by which this occurs in the genital mucosa
may be minimal (Ballweber et al., 2011; Kawamura et al., 2008).
Signiﬁcant populations of macrophages, known to be HIV-1 re-
servoirs (Abbas et al., 2015), are found in the sub-epithelium and
lamina propria (Lederman et al., 2006; Shattock and Moore, 2003).
Studies using human explants showed that macrophages are themain target of R5-tropic HIV-1 in the genital mucosa (Cummins
et al., 2007; Greenhead et al., 2000). Furthermore, macrophages
can trap the virus using the syndecans receptor or internalize it by
micropinocytosis (Marechal et al., 2001). The sub-epithelium and
lamina propria also host CD4þ T cells that are as well found within
the epithelial cell lining (Edwards and Morris, 1985; Johansson
et al., 1999). As shown by McElrath et al. these cells are key HIV-1
targets in the outer epithelial cell lining (McElrath et al., 2010).
Although within the genital mucosa CD4þ T cells are located in
close proximity to LCs studies showed that their initial infection is
not dependent of these cells (Hladik et al., 2007). Most CD4þ T
cells in this tissue are memory T cells that express high level of the
CCR5 receptor (Hladik et al., 1999b, 2007; Prakash et al., 2001).
Lastly, dendritic cells (DCs) are also located in the sub-epithelium
and lamina propria (Lederman et al., 2006; Miller and Shattock,
2003; Shattock and Moore, 2003). Genital mucosa DCs belong to
the same family as LCs. However, HIV-1 entry in these two cell
types may be mediated by different pathways since DCs express
the CXCR4 and DC-SIGN receptors while LCs do not (Geijtenbeek
et al., 2000; Hladik et al., 1999a; Jameson et al., 2002; Prakash
et al., 2004). DCs can bind and internalize HIV-1 via the DC-SIGN
receptor (Pohlmann et al., 2001a, 2001b) or they can be produc-
tively infected by the virus as studies in macaques showed (Hu
et al., 2000, 1998; Spira et al., 1996). This was supported by ob-
servations that tissue biopsies of vaginal stroma from HIV-positive
asymptomatic women contained infected DCs (Bhoopat et al.,
2001). These cells disseminate the virus via transfer to CD4þ T
Fig. 2. HIV-1 transmission through the epithelial cell lining. (A) HIV-1 transmission through physical abrasion such as those caused by sexual intercourse induced mi-
crotrauma. (B) Mechanism of transmission by direct infection and transcytosis. Once in the sub-epithelium the virus can infect macrophages, CD4þ T cells or bind dendritic
cells that facilitate its systemic dissemination.
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et al., 2004; Jolly and Sattentau, 2004, 2007; McDonald et al.,
2003). DCs can also transfer the virus to CD4þ T cells via contacts
between the tips of these cells nanotubes (Hope, 2007; Sherer
et al., 2007).
Most HIV-1 infections occur through the female genital tract
that contributes 12.6 million of cases worldwide (Hladik and
McElrath, 2008). However, the probability of infection per ex-
posure in this location is less than in other sites such as the rectum
or upper gastrointestinal tract (Hladik and McElrath, 2008). The
female genital tract has various defence mechanisms that can in-
activate the virus or provide physical and chemical barriers against
it. Amongst these are: (i) its acidic pH due to the presence of lactic
acid produced by resident lactobacilli (Aldunate et al., 2013;
O’Hanlon et al., 2013); (ii) the stratiﬁed structure of its epithelial
cell lining (Coombs et al., 2003; Miller and Shattock, 2003), which
is impenetrable to particles the size of HIV-1 (Marx et al., 1996;
Shattock and Moore, 2003; Smith et al., 2000); and (iii) the mucussecreted by cervicovaginal epithelial cells that can prevent the
virus from interacting with its target cells (Shukair et al., 2013) and
contains anti-HIV-1 proteins such as the secretory leukocyte pro-
tease inhibitors, lactoferrin, human-β-defensin (HBD-1) and lyso-
zyme (Cohen et al., 1987; Schumacher et al., 1977; Turpin, 2002).
Lastly, endocervical cells express the CXCR4 ligand SDF-1 that is
inhibitory to X4 HIV-1 viruses (Agace et al., 2000).
In females, heterosexual transmission of HIV-1 begins when
cell-free or cell-associated viruses are released into the genital
tract and infect target cells (Lederman et al., 2006; Stein, 2003).
HIV-1 can be transmitted via both the cervix and vaginal tract. This
is supported by the fact that cervical ectopy, caused by damage in
the epithelial cell lining, has been associated with increased risk of
infection (Miller et al., 1993); and the report of virus transmission
in a woman suffering from the Meyer-Rokitansky-Küster-Hauser
syndrome, a congenital disorder that results in the lack of a uterus
(Kell et al., 1992). Moreover, there were observations that the in-
oculation of cell-free simian immunodeﬁciency virus (SIV) into the
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(Miller et al., 1994). However, it is possible that HIV-1 infection
predominantly occurs in the vaginal tract since a clinical trial
showed that women who blocked the virus exposure to the cervix
by use of a diaphragm did not have a signiﬁcant reduction in
transmission (Padian et al., 2007).
Different mechanisms have been proposed to explain how
viruses released into the vaginal tract cross the epithelial cell
lining to infect cells in the lamina propria and sub-epithelium.
Among these, the breach of the genital mucosa during sexual
penetration is widely accepted as the main route of infection
(Fig. 2A) (Coombs et al., 2003; Miller and Shattock, 2003; Shattock
and Moore, 2003). When breached, intraepithelial LCs get exposed
to HIV-1 and migrate to the sub-epithelium and lymph nodes, to
disseminate the virus (Miller and Shattock, 2003). The rupture of
this lining can also directly expose sub-epithelial DCs to the virus
resulting in subsequent dissemination (Piguet and Sattentau,
2004; Pohlmann et al., 2001a, 2001b). Other proposed mechan-
isms include the direct infection of epithelial cells and transcytosis,
the passing of the virus through a cell without infecting it (Fig. 2B)
(Shattock and Moore, 2003). HIV-1 has been reported to migrate
through narrow gaps between epithelial cells to reach cells con-
stituting the basal layer that are more susceptible to transcytosis
(Maher et al., 2005). Among receptors that may promote the virus
attachment and subsequent transcytosis are the two surface gly-
cosphingolipids, sulphated lactosylceramide, found on vaginal
epithelial cells, and galactosylceramide, expressed by ectocervical
epithelial cells (Bomsel, 1997; Yeaman et al., 2004). However, it
should be noted that transcytosis has been shown in cell lines and
primary cells only but not conclusively in intact tissues (Bobardt
et al., 2007; Bomsel, 1997). Furthermore, some studies suggested
that primary cervical and vaginal epithelial cells do not get in-
fected by HIV or transcytosis (Dezzutti et al., 2001; Greenhead
et al., 2000).3. HIV-1 microbicide candidates
3.1. Vaginal milieu protectors
During sexual intercourse the release of semen increases the
pH in the female genital tract, which neutralizes vaginal acidity
and renders the environment favourable for HIV-1 infection (Tevi-
Benissan et al., 1997). Thus, buffering agents are designed to
counteract this process. BufferGel™ or Carbopol 974 (BufferGel,
ReProtect, Baltimore, MD, USA) is a carbopol polymer formulated
with a buffering agent that has the ability to buffer twice its vo-
lume in semen to pHr5. This is a microbicide candidate designed
to maintain the acidic pH of the vaginal tract. Although, clinical
trials in India, Thailand, Malawi and Zimbabwe showed that Buf-
ferGel™ destroys bacteria that cause vaginosis (Turpin, 2002), this
formulation has no effect on resident bacterial populations such as
lactobacilli. BufferGel™ has already passed two phase I safety trials
(Mayer et al., 2001). It also proved to be safe during a penile tol-
erance study with HIV-1 infected and uninfected men (Tabet et al.,
2003). However, BufferGel was unable to prevent HIV-1 trans-
mission during a clinical trial conducted in Southern Africa and
USA (Abdool Karim et al., 2011). Like BufferGel™, Acidform™ is a
buffering agent that was originally designed for use as a sexual
lubricant (Cutler and Justman, 2008; Ndesendo et al., 2008).
Acidform™ passed two phase I safety trials and one penile toler-
ance trial (Amaral et al., 1999, 2006; Schwartz et al., 2005). Cur-
rently there is a phase III trial underway with this buffering agent
(Bayer and Jensen, 2014).3.2. Surfactants
Surfactants solubilise bacterial and viral membranes, therefore,
rendering them inactive. C31G or SAVVYs (Cellegy Pharmaceu-
ticals, Quakertown, PA, U.S.A), made of cetyl betaine and myr-
istamine oxide, is one of the well-known surfactants (Cutler and
Justman, 2008). This compound most important characteristic is
the ability to dissolve and spread quickly through the genital
mucosa (Turpin, 2002). Besides its anti-viral activities, C31G is also
a spermicide and this may limit its use in women who want to
conceive or communities that stand against contraception (Calis
et al., 1992; Krebs et al., 1999). Two phase III trials with C31G in
Ghana and Nigeria were abandoned because of lower than ex-
pected rate of HIV-1 seroincidence in the selected populations
(Cutler and Justman, 2008). Nonoxynol-9 (N-9) is also a well-
known surfactant studied for use as HIV-1 microbicide. Two phase
III trials were conducted with N-9 in Africa. One trial amongst sex
workers showed no difference in the rate of HIV-1 infection be-
tween the study and the placebo group. However, this study found
an association between N-9 and a higher incidence of genital ul-
cers among trial participants (Roddy et al., 1998). The other trial
tested the use of 52.5 mg of gel-formulated N-9 that had to be
applied before and after sexual intercourse. Contrary to the pre-
vious study this latter found a 50% increase in the risk of con-
tracting HIV-1 in the study group (Statement on results of pro-
ducts containing N-9 from the CDC, 2000). The risk was even
higher in womenwho reported a reduced use of condom. This was
believed to be due to N-9 induced superﬁcial de-epithelialisation,
changes in genital microﬂora, high rate of petechial haemorrhage
and erythemia. These ﬁndings were supported by Van Damme
et al. randomised placebo controlled triple-blinded trial conducted
in four African countries and Thailand (Van Damme et al., 2002).
This study reported that enhanced use of N-9 increased the breach
of genital epithelial cell lining as well as the risk of HIV trans-
mission. This work, thus, gave the ﬁnal verdict on the demerit of
N-9 as a HIV-1 microbicide candidate. Another surfactant studied
as microbicide is sodium lauryl sulphate, which is liquid at room
temperature and converts into a gel that coats the vaginal tract at
body temperature (Cutler and Justman, 2008; Piret et al., 2000).
The results of a phase II trial conducted in Cameroon showed that
this microbicide candidate could be used for extended periods
without signiﬁcant adverse effects (Mbopi-Keou et al., 2009). This
was supported by another extended phase II safety trial, also in
Cameroon, that found sodium lauryl sulphate safe and acceptable
when used intravaginally twice daily for two months (Mbopi-Keou
et al., 2010).
3.3. Polyanionic polymers
Polyanionic polymers inhibit infection by interacting with the
positively charged V3 loop of HIV-1 gp120 (Doms, 2000; Doms
and Trono, 2000; Turpin, 2002). The binding of these compounds
to the virus is enhanced by the conformational changes that un-
mask charged regions of gp120 during entry into target cells
(Doms and Trono, 2000). Naphthalene sulfonate (PRO2000; In-
devus Pharmaceuticals, Lexington, MA, USA) and the seaweed
derived sulphated polysaccharide carrageenan (Carraguard/515,
Population Council, New York, NY, USA) are the most studied
polyanionic polymers (Cutler and Justman, 2008; Turpin, 2002).
PRO2000 passed a phase I safety trial (Van Damme et al., 2000)
but failed a phase III efﬁcacy trial in Southern Africa and the
United States (Abdool Karim et al., 2011; McCormack et al., 2010;
Ramjee, 2010). Carraguard showed anti-HIV activities in a mouse
model and proved to be safe in a phase I trial conducted with both
HIV-positive and negative individuals (Bollen et al., 2008; Coggins
et al., 2000; Perotti et al., 2003; van de Wijgert et al., 2007).
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et al., 2008). It was speculated that poor adherence to carraguard
by trial participants might have contributed to the observed lack of
efﬁcacy. Cellulose sulphate (Ushercell, Polydex Pharmaceuticals,
Toronto, ON, Canada and Topical Prevention of Conception and
Disease [TOPCAD], Chicago, IL, USA) is also among polyanionic
polymers studied as potential HIV-1 microbicides due to its strong
anti-viral activities against both X4 and R5 HIV-1 viruses (Scordi-
Bello et al., 2005). However, although a phase I trial showed cel-
lulose sulphate to be safe for use in humans (Malonza et al., 2005)
the results of a phase III trial indicated that there was a slightly
higher incidence of infection in the cellulose sulphate group
compared to placebo (Van Damme et al., 2008); and this led to it
being abandoned as a microbicide candidate. Cellulose acetate
phthalate (CAP) is a polyanionic polymer that binds HIV-1 gp120
resulting in the formation of the hybrid six helix conformation, an
intermediate in the virus entry (Melikyan et al., 2000). However,
this six-helix bundle is premature and non-functional. CAP also
has a unique ability to synergize with soluble CD4 (sCD4) to inhibit
HIV-1 infection (Neurath et al., 2002). These compounds where
shown to enhance each other's binding to the viral envelope as
well as to induce the six-helix bundle by cooperativity. A major
limitation of CAP is that it also increase infection of HIV-1 R5
strains in vitro (Tao et al., 2008). In addition, many women in the
CAP gel acceptability study complained of heavy discharge (Mi-
crobicides 2008 Conference, New Delhi, India, Abstract No. 527).
Betacyclodextrin (BCD) is a polyanionic polymer that depletes
cholesterol from lipid rafts found in the cell membrane and HIV-1
envelope (Graham et al., 2003; Kilsdonk et al., 1995). Given that
the CD4 receptor is located in these rafts, an interference with
their integrity inhibits viral entry (Liao et al., 2001; Popik et al.,
2002). The main advantages of using BCD as a microbicide include
its low cost and the fact that it is already used as a carrier for other
FDA-approved drugs (Bibby et al., 2000). A study in rhesus ma-
caques showed that BCD is protective against SIV challenge (Am-
brose et al., 2008). However, this compound failed to protect the
same animals when challenged for the second time.
Dendrimers are the newest members of the polyanionic poly-
mer family. These compounds are able to bind multiple locations
on different cells at the same time (Bourne et al., 2000). Den-
drimers are made of a core, interior branches and terminal surface
groups for selective interaction with speciﬁc targets (Bourne et al.,
2000). SPL7013 is a dendrimer gel (Vivagel, Starpharma Holdings
Ltd., Melbourne, Australia) that showed protection against the si-
mian/human immunodeﬁciency virus (SHIV) chimera in a maca-
que model (Jiang et al., 2005). A 3% formulation of this gel also
showed safety in a phase I trial in USA (McGowan et al., 2011). G3-
S16 and G2-NF16 are sulphated and naphthylsulfonated functio-
nalized carbosilane dendrimers that are as well being investigated
for potential use as microbicides (Vacas-Cordoba et al., 2016; Vacas
Cordoba et al., 2013). These relatively new dendrimers act by in-
hibiting HIV-1 binding and fusion with target cells. They also in-
hibit cell-to-cell transmission of the virus.
3.4. Reverse transcriptase inhibitors
Reverse transcriptase inhibitors (RTI) interfere with the con-
version of the viral RNA into DNA. This group of drugs include
nucleoside reverse transcriptase inhibitors (NRTI) and non-nu-
cleoside reverse transcriptase inhibitors (NNRTI). Tenofovir is a
NRTI that mimics an adenosine nucleotide (De Clercq, 2007) and
once incorporated into the nascent HIV-1 cDNA prematurely ter-
minates chain elongation. This drug has a cellular half-life of 9–
50 h depending on the cell type and can be effective in non-di-
viding cells such as macrophages that have limited phosphoryla-
tion ability (Aquaro et al., 2002; Balzarini et al., 1991; Robbinset al., 1998). A study using macaques showed that pre- and post-
exposure prophylaxis with tenofovir protects against intravenous
challenge with SIV (Tsai et al., 1995). This report was among the
ﬁrst to provide evidence that tenofovir could be used for HIV-1
prevention. Since then tenofovir has become one of the leading
antiretrovirals in HIV-1 microbicide research. A clinical trial con-
ducted in South Africa, using 1% tenofovir gel within 12 h before
and after sex (CAPRISA 004 trial), showed protection against het-
erosexual transmission of the virus (Abdool Karim et al., 2010).
More precisely, after 30 months of trial the gel prevented trans-
mission by 39%. The study also revealed that women with higher
adherence to the gel were better protected compared to those
with low adherence. HIV-1 RNA genotyping of women who got
infected during the trial did not reveal the presence of tenofovir
resistance mutations suggesting that vaginal application of the gel
did not give rise to resistant viruses (Abdool Karim et al., 2010).
However, it is not yet known what will result after a longer term
use of the drug. The VOICE trial using the same formulation of
tenofovir concluded that it did not protect against the sexual
transmission of HIV-1 although this trial also reported poor ad-
herence among participants (Marrazzo et al., 2015; Quinones-
Mateu and Vanham, 2012). Lastly, the FACTS 001 trial in South
Africa, enrolling 2, 900 women between the ages of 18 and 40
years old (www.facts-consortium.co.za), aimed at conﬁrming the
CAPRISA 004 results also reached the conclusion that tenofovir did
not prevent HIV-1 transmission (Helen Rees presentation at CROI
2015: Tenofovir Vaginal Gel Not Effective Overall Against HIV).
However, similar to CAPRISA 004, this study reported an associa-
tion between higher adherence and stronger protection against
the virus. Nonetheless, a recent study by Hladik et al. (2015) re-
ported potential toxic effects associated with the use of 1% teno-
fovir microbicide gel. Using vaginal and rectal mucosal tissues,
these researchers showed that the gel suppressed anti-in-
ﬂammatory mediators, increased T lymphocytes inﬁltration of the
mucosa, and induced mitochondrial dysfunction. In addition, te-
nofovir promoted the expression of genes associated with growth
of cancer cells, KIAA0101 and UBD (Hladik et al., 2015; Jain et al.,
2011). The toxic effects were observed only with high concentra-
tions of the drug and not with low ones such that are taken orally.
The thiocarboxanilide derivative UC-781 is a NNRTI character-
ized by high afﬁnity for HIV-1 reverse transcriptase. Cells treated
with UC-781 in vitro showed long term or “memory” protection
against HIV-1 (Balzarini et al., 1998; Barnard et al., 1997; Borkow
et al., 1997). Also UC781 is very hydrophobic, thus, able to easily
penetrate the viral envelope and enter the capsid to bind reverse
transcriptase even before entry into target cells (Borkow et al.,
1997; Zussman et al., 2003). A phase I trial evaluating a once-daily
dose of this compound for six days proved that it was safe for use
in humans (Schwartz et al., 2008). Recently, McConville et al. in-
vestigated the use of a vaginal ring for controlled release of UC-
781 (McConville et al., 2015). The ring was able to release enough
UC-781 capable of preventing the sexual transmission of HIV-1.
Moreover, their study in pigtailed macaques showed no toxicity
associated with this drug. Other NNRTI microbicide candidates
include SJ-3366 and TMC120 (Dapivirine). SJ-3366 is a homocyclic
pyrimidinedione that has a dual mode of action against HIV-1, it
inhibits both viral entry and reverse transcription (Turpin, 2002).
Dapivirine is the only microbicide candidate thus far to be tested
in humans as a vaginal ring (Gupta et al., 2008; Nel et al., 2016;
Spence et al., 2016; Woolfson et al., 2006). Phase 1 and 2 trials
with once monthly dapivirine vaginal ring application proved to
be safe and genital tissue biopsies of women using this drug
showed protection against ex-vivo challenge with HIV-1 (Chen
et al., 2015; Devlin et al., 2013; Nel et al., 2014). More recently, a
phase III clinical trial with dapivirine vaginal ring, conducted in
Uganda, Malawi, Zimbabwe and South Africa (MTN-020-ASPIRE
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virus (Baeten et al., 2016). Similar to CAPRISA 004 and FACTS trials
(Abdool Karim et al., 2010) (Helen Rees presentation at CROI 2015:
Tenofovir Vaginal Gel Not Effective Overall Against HIV), higher
adherence corresponded to higher protection against viral trans-
mission. Moreover, the MTN-020-ASPIRE trial reported a sig-
niﬁcant difference in protection and adherence between age
groups with a lack of protection and low adherence observed for
women in the 18-21 years old age group while a 56% protection
and adherence of over 70% were recorded for those older than 21
years of age. A second, dapivirine vaginal ring phase III trial is
currently underway (Baeten et al., 2016).
3.5. Proteins
Different proteins are being investigated for use as HIV-1 mi-
crobicides (Lederman et al., 2006). These are essentially entry in-
hibitors with varying modes of action against the virus. Some of
these proteins bind glycosylated and non-glycosylated regions of
the viral envelope while others interact with receptors on target
cells that are critical for infection. Grifﬁthsin (GRFT) is a lectin,
carbohydrate binding protein, isolated from the red alga Grifﬁthsia
sp. (Mori et al., 2005). This lectin is studied for use as a microbicide
due to its potent and broad activity against the virus (Alexandre
et al., 2010). GRFT is non-toxic to human cells and can be produced
in large quantities in plants (Kouokam et al., 2011; O’Keefe et al.,
2009). In addition, GRFT has the ability to synergize with other
HIV-1 inhibitors such as tenofovir (Alexandre et al., 2011; Ferir
et al., 2012, 2011) suggesting that it can be combined with these
compounds in a single more potent microbicide formulation. Due
to GRFT potency and efﬁcacy there are on-going discussions about
testing it in human clinical trials. Cyanovirin-N (CV-N) and scy-
tovirin (SVN) are also lectins, and like GRFT have shown potent
and broad inhibitory activities against HIV-1 (Alexandre et al.,
2010). Studies by Tsai et al. showed that a CV-N gel was effective in
protecting pigtailed macaques against SHIV 86.9P after vaginal and
rectal challenges (Tsai et al., 2004, 2003). However, there have
been conﬂicting reports on CV-N toxicity to human cells. Some
studies reported it to be toxic while others did not (Alexandre
et al., 2010; Balzarini et al., 2006). Large scale production of CV-N
in plants has been recently demonstrated, thus, promoting its use
as a microbicide (Vamvaka et al., 2016). Thus far, SVN studies have
been conducted exclusively in vitro.
PSC-RANTES potently binds the CCR5 co-receptor to inhibit
HIV-1 entry (Lobritz et al., 2013). This makes it an attractive mi-
crobicide candidate given that the sexual transmission of HIV-1 is
almost always initiated by R5 viruses. In vitro, this compound in-
hibits all subtypes of the virus (Torre et al., 2000) and in vivo a high
dose of PSC-RANTES was found to protect macaques against SHIV
SF162 challenge (Lederman et al., 2004). Another potential pro-
tein-based microbicide is the recombinant tetravalent construct
CD4-IgG2 or PRO-542 that is designed to bind the CD4 binding site
on gp120 and inhibit its interaction with the CD4 receptor (O’Hara
and Olson, 2002). Protein microbicide candidates also include the
chimeric protein syndecan-Fc, an inhibitor of HIV-1 binding to the
syndecan-1 receptor expressed on macrophages (Bobardt et al.,
2010); thrombospondin type I (TSP), a plasma protein that blocks
viral entry; and the pokeweed antiviral protein (PAP) that inhibits
HIV-1 replication.
Some monoclonal antibodies isolated from HIV-positive pa-
tients have demonstrated potent and broad anti-HIV-1 activities
that led to their inclusion among microbicide candidates. These
include b12, 4E10, VRC01, 2F5 and 2G12 (Veazey et al., 2003; Ve-
selinovic et al., 2012). Some of these antibodies have been suc-
cessfully produced in plants and shown to retain their anti-viral
activities (Ramessar et al., 2008; Rosenberg et al., 2013). This isimportant since a suitable microbicide needs to be produced in
large quantity and at a low cost.
Finally, PIE-12, C52L, RC-101, T20 and T1249 are peptides spe-
ciﬁc to the viral gp41 glycoprotein. These compounds have potent
anti-HIV-1 fusion activities and their suitability as microbicides is
being investigated (Pozzetto et al., 2012; Sassi et al., 2011; Veazey
et al., 2005; Welch et al., 2010).
3.6. Small molecules
Small molecules that are being studied for use as HIV-1 mi-
crobicide include CMPD167, a CCR5 inhibitor that showed strong
protective effects against SHIV in macaques (Veazey et al., 2005).
No irritation of the genital tract or toxicity was observed with the
use of this compound. In addition, the combination of CMPD167,
BMS-378806 that binds gp120 and C52L, a gp41 binder, resulted in
a synergistic inhibition of SHIV infection of macaques. Maraviroc is
a potent inhibitor of CCR5 interaction with HIV-1 (Maeda et al.,
2012). Its formulation as an aqueous gel or vaginal ring protected
macaques against SHIV acquisition (Malcolm et al., 2013, 2012).
Moreover, Maraviroc combination with a T-cell based vaccine
signiﬁcantly reduced both SHIV-SF162P3 infection and post-in-
fection viral load (Barouch et al., 2012). A potential drawback with
maraviroc use as a microbicide is that it is already used clinically to
treat HIV-1 infection. Its application as a microbicide in infected
individuals may give rise to resistant strains.
3.7. Nucleic acids
Aptamers are synthetic, single-stranded DNA and RNA mole-
cules that fold into unique 3-D structures to allow high afﬁnity
binding to target molecules (Ellington and Szostak, 1990; Proske
et al., 2005; Temme and Krauss, 2015; Zhang et al., 2004). These
oligonucleotides are synthesized through systematic evolution of
ligands by exponential enrichment (SELEX) to virtually recognize
any class of targets (Bunka and Stockley, 2006; Ellington and
Szostak, 1990; James, 2001; Jayasena, 1999; Proske et al., 2005;
Tuerk and Gold, 1990; Zhang et al., 2004). This makes aptamers
attractive as potential HIV-1 microbicides given that they can be
made to bind any site on the virus.
We previously isolated 2′-ﬂuoro-substituted RNA aptamers
against recombinant HIV-1BaL gp120 and showed that they neu-
tralized infection of group M (subtypes A, C, D E and F) and group
O R5 HIV-1 (Khati et al., 2003). We also showed that derivatives of
one of these aptamers, called UCLA1 and UCLA005, were potent
inhibitors of the virus (Cohen et al., 2008; Dey et al., 2005; Muf-
handu et al., 2012). In addition, UCLA1 exhibited synergism with
other anti-HIV-1 compounds such as T20 and the monoclonal
antibody b12 (Mufhandu et al., 2012). Some researchers have
conjugated aptamers to different inhibitory molecules to improve
activity. For example Wheeler and colleagues engineered CD4-
aptamer-siRNA chimeras (CD4-AsiCs) that potently inhibit HIV-1
(Wheeler et al., 2011). The aptamer in CD4-AsiCs, binds the V4
domain of gp120, the CD4 portion blocks gp120 interaction with
the CD4 receptor, while the siRNA inactivates Gag, Vif and CCR5 to
block the expression of genes required for viral replication (Kraus
et al., 1998; McNamara et al., 2006; Wheeler et al., 2011). CD4-
AsiCs inhibited HIV replication in macrophages (MDMs) and could
penetrate the vaginal epithelium to knock down viral gene ex-
pression in CD4þ T cells (Wheeler et al., 2011). The topical use of
this compound was also reported to protect humanized mice,
NSG-BLT mice, against vaginal challenge with HIV-1 (Wheeler
et al., 2013).
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The vagina and cervix are made of various natural defences that
need to be taken into consideration when designing a microbicide
delivery system as they can compromise the efﬁciency of delivery.
For example the secretion of vaginal ﬂuids can lead to leakages
that may decrease drug retention time; and the presence in the
vaginal mucosa of enzymes such as aminopeptidase (Acarturk
et al., 2001) can cause the degradation of peptides and proteins.
Below are the main delivery systems studied to date.
4.1. Gels
Semisolid gels are the most commonly used HIV-1 microbicide
delivery systems (Abdool Karim et al., 2010; Elias and Coggins,
1996; Van Damme et al., 2000). Often they are based on water
soluble polymers such as the cellulose derivative hydroxyl ethyl
cellulose or the polyacrylic acid derivative carbopol 974 (das Neves
and Bahia, 2006; Jarrett et al., 2016). Gels have the advantage of
being simple to use and show high consistency of drug delivery
(das Neves and Bahia, 2006; Ndesendo et al., 2008) since they can
spread easily. Also their viscosity and elasticity enhance drug
stability and retention. However, one of their most important
disadvantages is the tendency to be messy and leaky resulting in
low adherence (Primrose et al., 2016). Gels are mainly designed for
application before sexual intercourse, although, they can also be
used after sex (Abdool Karim et al., 2010).
4.2. Vaginal rings
Vaginal rings, containing one or more anti-HIV-1 compounds,
are used for controlled release of drugs into the genital tract over
long periods of time (Rohan and Sassi, 2009). These rings can
consist of polymers such as poly (dimethylsiloxane), silicon,
ethylene vinyl acetate and styrene butadiene. One of the key ad-
vantages of vaginal rings is that they provide an alternative to
users sustained adherence since once inserted into the genital
tract they continuously release the drug for long durations without
requiring intervention (Baeten et al., 2016). Furthermore, vaginal
rings are already used to deliver hormones and contraceptives into
the female genital tract (Thurman et al., 2013). However, the most
signiﬁcant limitations of this system are its cost, since vaginal
rings are complex and expensive to manufacture, and the fact that
some compounds have limited diffusion through the polymeric
matrix (Malcolm et al., 2010).
4.3. Vaginal ﬁlms
Perhaps a solution to the messy and leaky characteristics of gels
is the use of vaginal ﬁlms which are applied in much smaller
quantities. Because of this, vaginal ﬁlms have a higher likelihood of
acceptability among women than gels (Elias and Coggins, 2001).
Films dissolve very rapidly once in contact with vaginal ﬂuids al-
lowing for a faster release of drugs. In addition, their application
does not require the use of an applicator, thus, making them in-
herently less expensive than gels. The drawback with this system,
however, is the fact that vaginal ﬁlms have low overall mass that is
limiting for anti-viral agents requiring high dosage (Akil et al.,
2011; Mahalingam et al., 2011; Sassi et al., 2011). Moreover, there
is a potential for physical abrasion from ﬁlms sharp corners and
edges.
4.4. Tablets and suppositories
Tablets and suppositories are designed to release the micro-
bicidal agent by melting in the genital tract. With these systemsthe microbicide can be delivered over several hours. Tablets are
often formulated with mucoadhesive polymers to increase their
retention time (Ndesendo et al., 2008). Recently, McConville et al.
designed a multi-layered tablet capable of releasing, at in-
dependent rates, the antiretroviral dapivirine, the contraceptive
hormone levonorgestrel and the herpes simplex virus 2 inhibitor
acyclovir (McConville et al., 2016). The main advantage of using
tablets and suppositories is that they are already employed to
deliver intravaginal drugs. For example, cervical ripening prior to
child birth is achieved by use of the misoprostol suppository and
prostaglandin E2 tablet (Khoury et al., 2001; Taher et al., 2011).
However, the disadvantage of using this system is the possibility of
leaving granny residues in the vaginal tract following dissolution
(Garg et al., 2003).
4.5. Nanoparticles
The nanoparticles delivery system involves attaching an or-
ganic particle or noble-metal such as silver to an anti-HIV-1 mo-
lecule to be delivered into the genital tract. One of this system
advantages is the ability to protect the attached compound against
biodegradation and to facilitate its penetration into HIV-1 sus-
ceptible sites. PSC-RANTES has been studied for delivery via na-
noparticles (Ham et al., 2009). Using human ectocervical tissues
Ham et al. showed that PSC-RANTES encapsulated into nano-
particles had a 4.8 times greater uptake than its nonencapsulated
counterpart (Ham et al., 2009). Also Lakshmi et al. studied lacto-
ferrin nanoparticles carrying the anti-HIV-1 drug efavirenz and the
anti-microbial-spermicidal curcumin for use as microbicide
(Lakshmi et al., 2016). This formulation did show inhibitory ac-
tivities against HIV-1 and no toxicity to vaginal tissues and re-
sident Lactobacilli.
4.6. Electrospun ﬁbers
Electrospun ﬁbers are a relatively new platform for delivery of
HIV-1 microbicides (Ball et al., 2012; Blakney et al., 2013; Huang
et al., 2012). These are polymers generated by electrospinning that
can be engineered to incorporate multiple agents via composites
and to facilitate controlled release of anti-viral drugs for periods
ranging from 15 min to several days (Blakney et al., 2013). More-
over, electrospun ﬁbers can be made in various forms and me-
chanical properties allowing for user centered designs. The activ-
ities of electrospun ﬁbers loaded with tenofovir dipivoxil fumarate,
etravirine, and maraviroc have been studied in vitro (Ball et al.,
2016; Ball et al., 2012; Ball and Woodrow, 2014; Huang et al.,
2012). However, the retention of these ﬁbers in the vaginal vault
and toxicity to the genital mucosa require further investigation.5. Conclusion
There are many compounds targeting different stages of HIV-1
life cycle that are being studied for use as microbicides. However,
the critical challenge with these studies is the progress from in
vitro to human trials. The implementation of these trials is often
slow; one of the main reasons being high costs. There are also
socio-economic and cultural challenges that come with these
studies (MacQueen et al., 2016; Mensch et al., 2016). All these
challenges will inevitably have a negative impact on progress in
HIV-1 microbicides research. Therefore, the onus is on govern-
ments, business leaders, non-governmental organizations, scien-
tists, and community leaders to fund microbicide research and/or
help educate populations where trials are to be conducted in order
to accelerate their implementations. Here, studies similar to the
one conducted by Primrose et al., on drivers of vaginal drug
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2016). Such studies should be conducted within each population
targeted for trials in order to determine beforehand which mi-
crobicide vehicle and application routines are likely to have high
acceptability.
In future microbicides research envelope inhibitors and other
anti-HIV-1 compounds not used for the treatment of infection
should be given more prominence. It is a genuine concern that the
use of antiretrovirals as microbicides may in the long term give
rise to resistant viruses. This threatens to render the primary use
of these drugs ineffective. Lectins are among the most promising
envelope inhibitors studied as potential HIV-1 microbicides. Many
of these compounds have a broad spectrum of activity against the
virus, showed no toxicity to human cells (Alexandre et al., 2010;
Kouokam et al., 2011), have a high genetic barrier to resistance
(Alexandre et al., 2010, 2013) and are cheap to produce (O’Keefe
et al., 2009; Vamvaka et al., 2016). It is, therefore, important that
there be more support and diligence in getting these molecules
into animal and human trials.
Aptamers can inhibit their targets through interactions that are
superior, in speciﬁcity and afﬁnity, than many biologics and small
molecules (Nimjee et al., 2005; Shum et al., 2013). They also do not
have the toxicity and immunogenicity associated with some of
these agents. However, research with these molecules as micro-
bicides is not as advanced as it is for other compounds. Thus, more
ﬁnancial and human resources need to be channelled to studying
these highly ﬂexible and potent compounds for use as HIV-1
microbicides.
In future, more animal and human trials with microbicide
formulations combining different classes of anti-HIV-1 molecules
should be conducted. Such formulations may provide better pro-
tection against the virus than a single compound. This is supported
by several in vitro studies that showed synergistic effects between
some HIV-1 inhibitors (Ferir et al., 2011; Tremblay et al., 2000). For
example, we previously reported that the microbicide candidate
GRFT and the b12 antibody act synergistically to inhibit HIV-1
(Alexandre et al., 2011). Also a microbicide formulation containing
maraviroc and reverse transcriptase inhibitors resulted in en-
hanced activities of maraviroc and inhibited viruses that are re-
sistant to this drug in cellular and colorectal explant models
(Herrera et al., 2016). Furthermore, given the high rate of muta-
tions in the HIV-1 genome, whenever and wherever microbicides
are rolled out, we will inevitably reach the stage where we are
compelled to use more than one inhibitor in formulations to
achieve effective prevention. Thus, it is better for combined mi-
crobicides formulations to be investigated in trials now than wait
until the need for them arises.
Ziraﬁ et al. reported that human semen can reduce the in-
hibitory activities of some anti-HIV-1 compounds (Ziraﬁ et al.,
2014). More precisely this study showed semen exposed viruses
had 10–12 fold decrease in sensitivity to protease, integrase and
reverse transcriptase inhibitors, including tenofovir. This may be
one of the reasons why compounds that looked promising in vitro,
or even in animal trials, failed to protect during human trials
(Marrazzo et al., 2015; Tsai et al., 1995). It is, therefore, imperative
that all microbicide pre-clinical studies incorporate testing in the
presence of human semen.
To date, HIV-1 microbicides have been delivered mainly as gels.
However, given the negative effects that poor adherence has had
on many trial outcomes (Abdool Karim et al., 2010; Marrazzo et al.,
2015) it is important that delivery by vaginal ring be more fre-
quently used in clinical trials. These rings are the easiest and most
effective solution to poor adherence (Baeten et al., 2016; Nel et al.,
2016; van der Straten et al., 2016). Research on tablets, supposi-
tories and vaginal ﬁlms must also be accelerated since these sys-
tems can solve the problem of leakage, a key determining factorfor acceptability and consequently adherence (Primrose et al.,
2016). Ultimately the ideal would be for the same microbicide to
be formulated in more than one delivery system to give the user a
greater choice range. This is better illustrated by the availability of
dapivirine gel, ﬁlm and ring (Baeten et al., 2016; Bunge et al.,
2016).
Regardless of challenges faced by HIV-1 microbicide research,
advances already made and the fact that microbicides potentially
offer the most effective alternative to the yet to be discovered HIV-
1 vaccine, strongly support our continued and increased invest-
ment in this ﬁeld.Acknowledgement
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